Curi Bio

💡 WHAT DOES IT LOOK LIKE WHEN THE SCIENCE SPEAKS FOR ITSELF? 🧬 At Curi Bio's Seattle Workshop 2026 on July 18, pharma, biotech and academic leaders gathered at our HQ for a day of science, live demos, and collaboration—sharing new data, asking sharp questions, and leaving convinced that 3D human engineered tissue technology is no longer the future of preclinical discovery. It's the present. Here's what they shared: 🔬 Mike Stauske, PhD — AstraZeneca delivered an industry-defining talk: "𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗼𝗻 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗶𝗻𝗴 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗛𝘂𝗺𝗮𝗻 𝗠𝗼𝗱𝗲𝗹𝘀 𝗶𝗻 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆" sharing cardiac safety screening data generated on Curi Bio's platform. 🔬 Monica Wang, PhD — UCB showed how 3D human skeletal muscle platforms are modeling DM1-associated myotonia: "𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗗𝗠𝟭-𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲𝗱 𝗠𝘆𝗼𝘁𝗼𝗻𝗶𝗮 𝗶𝗻 𝗮 𝟯𝗗 𝗛𝘂𝗺𝗮𝗻 𝗦𝗸𝗲𝗹𝗲𝘁𝗮𝗹 𝗠𝘂𝘀𝗰𝗹𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺." 🔬 Bee Pruzinsky, PhD — Cytokinetics showed how engineered muscle tissue is accelerating early-stage disease modeling: "𝗖𝗵𝗮𝗿𝗮𝗰𝘁𝗲𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗲𝗱 𝗠𝘂𝘀𝗰𝗹𝗲 𝗧𝗶𝘀𝘀𝘂𝗲 (𝗘𝗠𝗧) 𝗳𝗼𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗘𝗮𝗿𝗹𝘆-𝗦𝘁𝗮𝗴𝗲 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆." 🔬 Timothy Petrie, PhD — Novo Nordisk unpacked the data potential of higher-throughput: "𝗣𝗮𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵 𝗜𝗻: 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗛𝗶𝗴𝗵𝗲𝗿 𝗧𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝟵𝟲 𝗧𝗶𝘀𝘀𝘂𝗲 𝗣𝗹𝗮𝘁𝗲 𝗘𝘅𝗽𝗹𝗼𝗿𝗮𝘁𝗶𝗼𝗻." 🔬 Elizabeth Kahle, PhD — Novo Nordisk laid out a bold framework for what's next: "𝗧𝗼𝘄𝗮𝗿𝗱 𝗮𝗻 𝗔𝗜-𝗘𝗻𝗮𝗯𝗹𝗲𝗱 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝗸𝗲𝗹𝗲𝘁𝗮𝗹 𝗠𝘂𝘀𝗰𝗹𝗲 𝗙𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗧𝗮𝗿𝗴𝗲𝘁 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴." 🔬 David Mack, PhD — University of Washington anchored the scientific foundation: "𝗨𝘀𝗶𝗻𝗴 𝟯𝗗 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗲𝗱 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗮𝗻𝗱 𝗦𝗸𝗲𝗹𝗲𝘁𝗮𝗹 𝗠𝘂𝘀𝗰𝗹𝗲 𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝗳𝗼𝗿 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆." 🔬 Jacob Fleming — Curi Bio took the audience inside the frontier of next-generation models: "𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗡𝗲𝘂𝗿𝗼𝗺𝘂𝘀𝗰𝘂𝗹𝗮𝗿 𝗝𝘂𝗻𝗰𝘁𝗶𝗼𝗻 𝗠𝗼𝗱𝗲𝗹𝘀." The afternoon offered live product demons with the Curi Bio team on the floor to answer every question. 𝗧𝗵𝗶𝘀 𝗶𝘀 𝘄𝗵𝗮𝘁 𝗖𝘂𝗿𝗶 𝗕𝗶𝗼'𝘀 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗪𝗼𝗿𝗹𝗱 𝗧𝗼𝘂𝗿 𝗶𝘀 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿: bringing together the scientists driving real change in preclinical discovery, and giving them the tools and community to go further. Read the full blog recap 👉 https://hubs.ly/Q04rM2KV0 #DrugDiscovery #iPSC #MuscleBiology #3DTissue #DiseaseModeling #NAMs #TissueEngineering #PreclinicalResearch #CardiacModels #SkeletalM...

Happy #FluorescenceFriday! 🔬❤️ In 2026, we're all getting used to AI showing up in daily lives, sometimes where we least expect it. This time it showed up on a 𝗠𝗮𝗻𝘁𝗮𝗿𝗿𝗮𝘆. A recent preprint from a team at the University of Washington led by Professors Hannele Ruohola-Baker, David Mack, and Nobel Laureate David Baker used AI-designed protein "minibinders”, a cocktail called C6-DPC, to rewire receptor signaling and reprogram human fibroblasts into functional muscle. These immunofluorescence cross-sections of engineered muscle tissues (EMTs) show nuclei (🔵), myosin heavy chain (🟢), and dystrophin (🔴). 𝗪𝗵𝗮𝘁 𝘀𝘁𝗮𝗻𝗱𝘀 𝗼𝘂𝘁 𝗶𝗻 𝘁𝗵𝗲𝘀𝗲 𝗶𝗺𝗮𝗴𝗲𝘀: ➡️ Dystrophin-deficient (DMD) engineered muscle tissues lack the peripheral dystrophin localization around the myotubes seen in the controls.  ➡️ The C6-DPC minibinder cocktail produced denser, more organized myofiber architecture in both control and DMD tissues, which was reflected in the functional contractility data collected with Mantarray.  📌𝗕𝗼𝗻𝘂𝘀 𝗳𝗮𝗰𝘁: This study is a great example of a Mantarray user bringing their own cells and media formulations. We're happy to support you with ours, but the platform is flexible enough to run your own.   🔗 Read the publication: https://hubs.ly/Q04rpkmg0 #RegenerativeMedicine #MuscleBiology #ProteinDesign #DMD #CellReprogramming #ComputationalBiology #AIDrugDiscovery #Mantarray

𝐈𝐂𝐘𝐌𝐈: 𝐓𝐡𝐞 𝐩𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐢𝐬 𝐬𝐡𝐢𝐟𝐭𝐢𝐧𝐠 𝐟𝐚𝐬𝐭. 𝐈𝐬 𝐲𝐨𝐮𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨 𝐤𝐞𝐞𝐩𝐢𝐧𝐠 𝐮𝐩? Animal models frequently fail to translate, leaving biotech and pharma teams dealing with costly, late-stage failures. But leading innovators are already clearing these translation hurdles by pivoting to 3D human functional data. In our recent webinar, Dr. Christal Worthen and Thomas Leahy, PhD shared how Curi Bio’s Custom Research Services turn complex human biology into actionable, decision-driving data. Key Takeaways from the Session: ✅ 𝐒𝐩𝐞𝐞𝐝 𝐭𝐨 𝐃𝐚𝐭𝐚: How off-the-shelf 3D tissue models for DMD, DM1, and MYBPC3 eliminate months of tedious assay development. ✅ 𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐃𝐞𝐩𝐭𝐡: Unlocking automated, multi-parametric screening with sophisticated designs, including chronic dosing and washout conditions. ✅ 𝐁𝐮𝐢𝐥𝐭 𝐭𝐨 𝐒𝐩𝐞𝐜: A step-by-step workflow for building complex, multi-lineage human models from the ground up. Human functional data is rapidly becoming the standard in preclinical workflows. If you missed the live presentation, you can still catch all the insights on-demand. 🎥 Watch the full session here: https://hubs.ly/Q04qCsZs0 #CuriBio #NAMs #PreclinicalResearch #INDEnabling #DrugDiscovery #3DEngineeredTissues #Biotech #OnDemand

Connecting innovation across borders! 🧬🌏 𝗖𝘂𝗿𝗶 𝗕𝗶𝗼 𝗞𝗼𝗿𝗲𝗮 was honored to participate in the Thailand–Korea Business Forum: Biohealth, Medtech, Wellness, and Future Food, hosted at the Lotte Hotel in Seoul. Representing Curi Bio Korea, Montri Meeseepong, our Lead Applications Scientist, joined distinguished leaders, government officials, and industry pioneers to explore cross-border partnerships and business opportunities in biohealth and medical technology. Building strong international networks is at the core of driving transformative biohealth innovations. We look forward to turning these valuable discussions into impactful future collaborations! 🚀 Want to learn how Curi Bio supports APAC teams with advanced 3D tissue models, instrumentation, and analytic research solutions? Let’s connect. 🤝 https://hubs.ly/Q04qC5kF0 #CuriBio #Biohealth #Medtech #Biotechnology #ThailandKoreaBusinessForum #DrugDiscovery #GlobalInnovation #CellModels #BiotechPartnerships

Well there's certainly been some excitement at #AHABCVS! 🫀 Nelsa Estrella, Ph.D. enjoyed connecting with everyone at Poster 47 to share Curi Bio's latest hypertrophic cardiomyopathy (HCM) data and discuss the future of translational development. If you missed the presentation or want to keep the conversation going, Nelsa is in Boston for the rest of conference and her DM's are open to chat! Explore how our scalable 3D engineered heart tissue (EHT) platform can accelerate your cardiac drug discovery pipeline. 📅 Connect or schedule a meeting with Nelsa here: https://hubs.ly/Q04ppgR40 #AHABCVS #CardiovascularResearch #DrugDiscovery #3DEHT #InVitroModels #NAMs #cardiomyopathy

Attending AHA BCVS 2026 in Boston this week? 🫀 Connect with Nelsa Estrella, Ph.D., Curi Bio’s Director of Business Development, to learn how our human 3D engineered heart tissues (EHTs) are advancing genetic cardiomyopathy modeling and preclinical drug discovery. Dr. Estrella will be presenting Poster 47 on July 13, 4:30–7:00 PM, highlighting how our Mantarray platform models MYBPC3-driven hypertrophic cardiomyopathy (HCM) using a human MYBPC3e6 3D EHT model. This system recapitulates key clinical hallmarks of HCM, including: ✔️73% increase in twitch force ✔️Localized profibrotic remodeling ✔️Distinct calcium hypersensitivity These phenotypes are further validated by disease-appropriate drug responses, including phenotype normalization with mavacamten, demonstrating a scalable, human-relevant platform to accelerate cardiac drug discovery. 📍Meet with Dr. Estrella at Poster 47, or 📅 Schedule time to discuss how our 3D EHT platform can support your cardiac disease pipelines. 👉 Schedule here! https://hubs.ly/Q04pdY0Q0 #AHABCVS #CardiovascularResearch #DrugDiscovery #3DEHT #HypertrophicCardiomyopathy #InVitroModels #NAMs

⏳ Seven days. Three time points. One reproducible result. ✅ In our recent collaboration with 28bio, CNS-3D Brain Organoids were dosed with muscimol, washed out, and re-dosed, all captured on Curi Bio’s Nautilai 𝘗𝘭𝘶𝘴™ platform with full calcium transient profiles analyzed over the entire study window. The IC50 held steady on Day 0, Day 3, and Day 7, and suppression reversed cleanly every time. 𝗧𝗵𝗲 𝗴𝗼𝗮𝗹: demonstrate longitudinal, reproducible functional data from a 3D human brain model. 𝘛𝘩𝘦 𝘥𝘢𝘵𝘢 𝘥𝘦𝘭𝘪𝘷𝘦𝘳𝘦𝘥. 🧠 On July 22, join Thomas Leahy, PhD (Curi Bio) and Nicholas Coungeris, PhD (28bio) as they walk through the multi-compound study of dose–response kinetics, time-resolved imaging, and an end-to-end high-throughput workflow in a 384-well format. Are you working on CNS neurotoxicity or neuroactive compound screening? See how high-throughput functional imaging and 3D organoids can work together in practice. 📅 July 22 | 8:00 AM PDT / 11:00 AM EDT / 5:00 PM CET Register now 👉 https://hubs.ly/Q04nRsmk0 #Neuroscience #DrugDiscovery #BrainOrganoids #Preclinical #Neurotoxicity #NAMs

Curi Bio is on the ground in Florence, Italy for the 19th International Congress on Neuromuscular Diseases (ICNMD 2026), July 7–11, connecting with the global neuromuscular community to advance human-relevant disease models and drug discovery. 🇮🇹 Our Director of Business Development for Europe, Hamed Ghazizadeh, PhD is available throughout the congress for in-depth discussions on how Curi Bio's platforms like Mantarray™, Nautilai 𝘗𝘭𝘶𝘴™, and our neuromuscular and NMJ models, enable more predictive, human iPSC–based data for discovery, safety, and efficacy. 𝗜𝗳 𝘆𝗼𝘂’𝗿𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗜𝗖𝗡𝗠𝗗 𝗮𝗻𝗱 𝗮𝗿𝗲 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘁𝗲𝗱 𝗶𝗻: ✅ Translating benchtop neuromuscular insights into clinically meaningful data ✅ Integrating 3D human neuromuscular and NMJ models into your pipeline ✅ Leveraging functional contractility and calcium imaging readouts at scale Book time with Hamed here: 🔗 https://hubs.ly/Q04nR-9K0 We look forward to meeting colleagues and collaborators in Florence and exploring new ways to bridge the gap between in vitro discovery and clinical potential. Ciao! 🤝 #CuriBio #Mantarray #NautilaiPlus #DrugDiscovery #3DBioengineering #HumanRelevantData #iPSC #NeuromuscularDiseases #TranslationalResearch

In this webinar 28bio and Curi Bio will present new data demonstrating longitudinal functional profiling of CNS-3D Brain Organoids using high-throughput calcium imaging on the Nautilai Plus platform.   This workflow lets researchers track the same organoid model across repeated dosing cycles, revealing whether a compound's effect on network activity resolves after washout or persists over time.   Key Takeaways Run chronic dosing studies. Muscimol dosed, washed out, and re-dosed on Days 0, 3, and 7 produced a stable IC50 from Day 3 onward (0.15 uM, 0.14 uM).   Distinguish true toxicity from expected on-target effects. Reversible modulation across repeat dosing cycles is consistent with a pharmacological effect rather than accumulating damage.   Screen broader mechanism panels with the same assay. The same organoid model and imaging platform generated acute dose-response and kinetics data across four mechanistically distinct compounds. Register today: https://hubs.li/Q04nMMF30 #CNS

The preclinical landscape is shifting, and now is the time to make a difference in your research program. On July 14, Curi Bio's Dr. Christal Worthen and Thomas Leahy, PhD are pulling back the curtain on how biopharma teams are using 3D human tissue models to make faster, more confident go/no-go decisionw, before costly late-stage failures. Get a live look at the workflows, disease models, and study designs that are already moving preclinical programs forward. 𝗜𝗻 𝘁𝗵𝗶𝘀 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘄𝗲'𝗹𝗹 𝗰𝗼𝘃𝗲𝗿: ✔️ Off-the-shelf human models to assess therapeutic interventions or vector delivery in tissues with clinically relevant neuromuscular and cardiac mutations (DMD, DM1, MYBPC3) ✔️ Advanced multi-parametric screening with repeated dosing, washout tracking, and multi-lineage co-cultures to characterize complex cellular interactions. ✔️ Reproducible and regulatory-ready datasets generated by PhD scientists to keep your program on schedule. If you're still calibrating your preclinical strategy for 2026, this is the session you don't want to miss. 📅 Tuesday, July 14 · 8 AM PT / 11 AM ET / 5 PM CET Spots are filling up. Reserve your seat now: https://hubs.ly/Q04nF6920 #CuriBio #NAMs #DrugDiscovery #PreclinicalResearch #INDEnabling #3DEngineeredTissues